FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549
-------------	------	-------

CTATEMENIT	OF CHANCES	IN DENIETICIAL	OVANIEDCLIID
STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-0										
Estimated average I	ourden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Secor Alicia					2. Issuer Name and Ticker or Trading Symbol Orchard Therapeutics plc [ORTX]							(Che	elationship o eck all applic	′		on(s) to Issu 10% Ow		
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/14/2023								Officer below)	(give title		Other (sp below)	pecify	
C/O ORCHARD THERAPEUTICS PLC 245 HAMMERSMITH ROAD				4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person							
(Street)	•											Form filed by More than One Reporting Person						
(City)	(S	,	(Zip)			Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tak	ole I - Non-	Deriva	ative	Sec	curities	s Ac	quired, D	ispose	d of,	, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			Execution Date,		3. Transaction Code (Instr.) 8) 4. Securities Acquired (ADisposed Of (D) (Instr. 3) 5)		red (A) or str. 3, 4 and	Beneficia Owned F	es For ally (D) Following (I) (rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership						
								Code	/ Amo	unt	(A) c (D)	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Date, T Security or Exercise (Month/Day/Year) if any		Co	5. Number Derivative Securities Acquired (or Dispose of (D) (Inst 3, 4 and 5)		e s (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)		O U D	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Date Exercisable	Expiration Date	xpiration or		Amount or Number of Shares		(Instr. 4)									
Stock Option (Right to Buy)	\$0.495	06/14/2023			A		105,000		(1)	06/13/20	33 C S	Ordinary Shares ⁽²⁾	105,000	\$0.00	105,00	0	D	

- 1. All of the shares subject to this option vest upon the earlier to occur of June 14, 2024 or the date of the 2024 Annual General Meeting of the Company.
- 2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.

Remarks:

/s/ Frank Thomas, as attorneyin-fact

06/16/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.